EE04716B1 - Disubstituted bicyclic heterocycles, their preparation and use as pharmaceuticals - Google Patents
Disubstituted bicyclic heterocycles, their preparation and use as pharmaceuticalsInfo
- Publication number
- EE04716B1 EE04716B1 EEP199900359A EEP9900359A EE04716B1 EE 04716 B1 EE04716 B1 EE 04716B1 EE P199900359 A EEP199900359 A EE P199900359A EE P9900359 A EEP9900359 A EE P9900359A EE 04716 B1 EE04716 B1 EE 04716B1
- Authority
- EE
- Estonia
- Prior art keywords
- pharmaceuticals
- preparation
- bicyclic heterocycles
- disubstituted bicyclic
- disubstituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/70—Sulfur atoms
- C07D277/74—Sulfur atoms substituted by carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19706229A DE19706229A1 (en) | 1997-02-18 | 1997-02-18 | New aryl-substituted bi:cyclic heterocyclic compounds |
DE1997151939 DE19751939A1 (en) | 1997-11-24 | 1997-11-24 | New aryl-substituted bi:cyclic heterocyclic compounds |
PCT/EP1998/000865 WO1998037075A1 (en) | 1997-02-18 | 1998-02-16 | Disubstituted bicyclic heterocycles, their production and use as medicaments |
Publications (2)
Publication Number | Publication Date |
---|---|
EE9900359A EE9900359A (en) | 2000-02-15 |
EE04716B1 true EE04716B1 (en) | 2006-10-16 |
Family
ID=26034058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP199900359A EE04716B1 (en) | 1997-02-18 | 1998-02-16 | Disubstituted bicyclic heterocycles, their preparation and use as pharmaceuticals |
Country Status (39)
Country | Link |
---|---|
EP (1) | EP0966454B1 (en) |
JP (1) | JP3343359B2 (en) |
KR (1) | KR100619458B1 (en) |
CN (1) | CN1088702C (en) |
AR (1) | AR010896A1 (en) |
AT (1) | ATE239712T1 (en) |
AU (1) | AU742593C (en) |
BG (1) | BG64558B1 (en) |
BR (1) | BR9807843B1 (en) |
CA (1) | CA2277949C (en) |
CO (1) | CO4920237A1 (en) |
CZ (1) | CZ297768B6 (en) |
DE (2) | DE122008000020I1 (en) |
DK (1) | DK0966454T3 (en) |
EA (1) | EA003697B1 (en) |
EE (1) | EE04716B1 (en) |
EG (1) | EG24144A (en) |
ES (1) | ES2199426T4 (en) |
FR (1) | FR08C0025I2 (en) |
HK (1) | HK1025096A1 (en) |
HR (1) | HRP980082B1 (en) |
HU (1) | HU223754B1 (en) |
IL (1) | IL130812A (en) |
LT (1) | LTC0966454I2 (en) |
LU (1) | LU91437I2 (en) |
MY (1) | MY129408A (en) |
NL (1) | NL300349I2 (en) |
NO (3) | NO313879B1 (en) |
NZ (1) | NZ337323A (en) |
PE (1) | PE121699A1 (en) |
PL (1) | PL195551B1 (en) |
PT (1) | PT966454E (en) |
RS (1) | RS49686B (en) |
SA (1) | SA98190047B1 (en) |
SI (1) | SI0966454T1 (en) |
SK (1) | SK285432B6 (en) |
TR (1) | TR199902017T2 (en) |
TW (1) | TW588047B (en) |
WO (1) | WO1998037075A1 (en) |
Families Citing this family (171)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1608399A (en) * | 1997-11-26 | 1999-06-15 | Axys Pharmaceuticals, Inc. | Substituted amidinoaryl derivatives and their use as anticoagulants |
EP1060166A1 (en) * | 1998-02-03 | 2000-12-20 | Boehringer Ingelheim Pharma KG | Five-membered, benzo-condensed heterocycles used as antithrombotic agents |
US6114532A (en) * | 1998-02-03 | 2000-09-05 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals |
US6291514B1 (en) | 1998-02-09 | 2001-09-18 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors |
CA2321025A1 (en) * | 1998-02-09 | 1999-08-12 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines and guanidines as protease inhibitors, in particular as urokinase inhibitors |
TWI248435B (en) * | 1998-07-04 | 2006-02-01 | Boehringer Ingelheim Pharma | Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions |
US6248770B1 (en) | 1998-07-09 | 2001-06-19 | Boehringer Ingelheim Pharma Kg | Benzimidazoles having antithrombotic activity |
MXPA01008084A (en) * | 1999-02-09 | 2004-09-10 | Dimensional Pharm Inc | Heteroaryl amidines, methylamidines and guanidines as protease inhibitors. |
DE19907813A1 (en) * | 1999-02-24 | 2000-08-31 | Boehringer Ingelheim Pharma | Substituted bicyclic heterocycles, their preparation and their use as pharmaceuticals |
AR023510A1 (en) | 1999-04-21 | 2002-09-04 | Astrazeneca Ab | A TEAM OF PARTS, PHARMACEUTICAL FORMULATION AND USE OF A THROMBIN INHIBITOR. |
DE19939463A1 (en) * | 1999-08-20 | 2001-02-22 | Boehringer Ingelheim Pharma | Tryptase inhibitors useful e.g. for treating inflammatory or allergic disease, arteriosclerosis or neoplasia, comprising new or known 2-phenethyl-benzimidazole-5-carboxamides |
US6512000B1 (en) | 1999-08-20 | 2003-01-28 | Boehringer Ingelheim Pharma Kg | Aminocarbonyl-substituted benzimidazoles having tryptase-inhibitory activity |
DE19945787A1 (en) | 1999-09-24 | 2001-03-29 | Boehringer Ingelheim Pharma | New 2-(amidino- or aminomethyl-phenethyl)-5-sulfonylamino-benzimidazoles, are tryptase inhibitors useful e.g. for treating inflammatory or allergic disease such as asthma, urticaria or arthritis |
US6413990B1 (en) | 1999-09-24 | 2002-07-02 | Boehringer Ingelheim Pharma Kg | Arylsulphonamide-substituted benzimidazoles having tryptase-inhibiting activity |
JP2003510310A (en) * | 1999-09-24 | 2003-03-18 | ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト | Arylsulfonamide-substituted benzimidazole derivatives, methods for their preparation and their use as pharmaceutical compositions |
DE19945810A1 (en) * | 1999-09-24 | 2001-03-29 | Boehringer Ingelheim Pharma | Substituted benzimidazole derivatives, process for their preparation and their use as medicaments |
US6407130B1 (en) | 1999-11-10 | 2002-06-18 | Boehringer Ingelheim Pharma Kg | Carboxamide-substituted benzimidazoles having tryptase-inhibiting activity |
US6451832B2 (en) | 1999-12-23 | 2002-09-17 | Boehringer Ingelheim Pharma Kg | Benzimidazoles with antithrombotic activity |
US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
WO2002088092A1 (en) | 2001-04-19 | 2002-11-07 | Eisai Co., Ltd. | 2-iminoimidazole derivative (2) |
DE10133786A1 (en) * | 2001-07-16 | 2003-02-06 | Boehringer Ingelheim Pharma | Use of thrombin inhibitors for the treatment of arthritis |
ATE540943T1 (en) * | 2002-03-07 | 2012-01-15 | Boehringer Ingelheim Pharma | 3-Ä(2-ÄÄ4-(HEXYLOXYCARBONYLAMINO-IMINO-METHYL)- PHENYLAMINOÜMETHYLÜ-1-METHYL-1H-BENZIMIDAZOLE-5- CARBONYL)-PYRIDINE-2-YL-AMINOÜ-PROPIONIC ACID- ETHYL ESTER METHANESULPHONATE |
US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
DE10235639A1 (en) * | 2002-08-02 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New prodrugs of benzimidazole-5-carboxamide derivative thrombin inhibitor, useful for treating or preventing thrombotic diseases, are well tolerated on subcutaneous injection |
JP2005535710A (en) | 2002-08-09 | 2005-11-24 | トランス テック ファーマ,インコーポレイテッド | Aryl and heteroaryl compounds and methods for modulating coagulation |
PE20040804A1 (en) * | 2002-12-19 | 2004-12-31 | Boehringer Ingelheim Pharma | CARBOXAMID DERIVATIVES AS INHIBITORS OF THE Xa FACTOR |
US7429597B2 (en) | 2002-12-23 | 2008-09-30 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions |
DE10260730A1 (en) * | 2002-12-23 | 2004-07-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel substituted nitrogen-containing heterobicyclene, their preparation and their use as pharmaceuticals |
CA2515715C (en) | 2003-02-19 | 2012-05-08 | Eisai Co., Ltd. | Methods for producing cyclic benzamidine derivatives |
DE10310278A1 (en) * | 2003-03-10 | 2004-09-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New N-(benzazinyl)-(hetero)aralkylamine derivatives, are inhibitors of factor Xa and/or related serine proteases, useful e.g. as antithrombotic agents and intermediates |
EP1622621A2 (en) * | 2003-04-24 | 2006-02-08 | Boehringer Ingelheim International GmbH | Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors |
AU2004263508A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
WO2005014534A1 (en) * | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
DE10337697A1 (en) * | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablet containing 3 - [(2 - {[4- (hexyloxycarbonylamino-iminomethyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] - propionic acid ethyl ester or its salts |
DE10339862A1 (en) * | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New crystalline forms of ethyl 3-(N-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-N-(2-pyridyl)amino)propionate methanesulfonate used for post-operative prophylaxis of deep vein thrombosis |
DE10341043A1 (en) * | 2003-09-03 | 2005-03-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New Oral Dosage Form for 3 - [(2 - {[4-hexyloxycarbonylamino-imino-methyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] Propionic acid ethyl ester and its salts |
EP1609784A1 (en) * | 2004-06-25 | 2005-12-28 | Boehringer Ingelheim Pharma GmbH & Co.KG | Process for the preparation of 4-(benzimidazolylmethylamino)-benzamidines |
US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
DE102005020002A1 (en) * | 2005-04-27 | 2006-11-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New hexyloxycarbonylamino-imino-methyl-phenylamino-methyl-benzimidazole-pyridine-propionic acid-ethyl ester salts such as hydrochloride useful for the prophylaxis of vein thrombosis and stroke |
DE102005025728A1 (en) * | 2005-06-04 | 2006-12-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Polymorphs of 3 - [(2 - {[4- (hexyloxycarbonylamino-imino-methyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] -propionic acid ethyl ester |
ES2352796T3 (en) | 2005-06-27 | 2011-02-23 | Bristol-Myers Squibb Company | CYCLIC ANTAGONISTS UNITED TO C OF THE P2Y1 RECEIVER USEFUL IN THE TREATMENT OF THROMBOTHIC AFFECTIONS. |
DE102005061624A1 (en) * | 2005-12-21 | 2007-06-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Improved process for the preparation of salts of 4- (benzimidazolylmethylamino) -benzamidines |
DE102005061623A1 (en) * | 2005-12-21 | 2007-06-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Improved process for the preparation of 4- (benzimidazolylmethylamino) -benzamidines and their salts |
US8044242B2 (en) | 2006-03-09 | 2011-10-25 | Bristol-Myers Squibb Company | 2-(aryloxy) acetamide factor VIIa inhibitors useful as anticoagulants |
CN101500993A (en) | 2006-06-08 | 2009-08-05 | 百时美施贵宝公司 | 2-aminocarbonylphenylamino-2-phenilacetamides as factor VIIa inhibitors useful as anticoagulants |
JP2009543842A (en) * | 2006-07-17 | 2009-12-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | New indications for direct thrombin inhibitors in the cardiovascular field |
CA2657269A1 (en) * | 2006-07-17 | 2008-01-24 | Boehringer Ingelheim International Gmbh | New indications for direct thrombin inhibitors |
EP2074112A1 (en) * | 2006-10-10 | 2009-07-01 | Boehringer Ingelheim International GmbH | Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester |
JP5342450B2 (en) | 2006-12-15 | 2013-11-13 | ブリストル−マイヤーズ スクイブ カンパニー | Arylpropionamide, arylacrylamide, arylpropinamide, or arylmethylurea analogs as factor XIa inhibitors |
PE20081775A1 (en) | 2006-12-20 | 2008-12-18 | Bristol Myers Squibb Co | MACROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA |
EP1956018A1 (en) * | 2007-02-06 | 2008-08-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Method of preparing a derivative of benzimidazole |
KR20100015886A (en) | 2007-04-23 | 2010-02-12 | 사노피-아벤티스 | Quinoline-carboxamide derivatives as p2y12 antagonists |
WO2009018405A1 (en) * | 2007-07-31 | 2009-02-05 | Mallinckrodt Inc. | Integrated photoactive agents and uses thereof |
EP2238128B1 (en) | 2007-12-26 | 2012-08-22 | Sanofi | Heterocyclic pyrazole-carboxamides as p2y12 antagonists |
CZ305085B6 (en) * | 2008-03-14 | 2015-04-29 | Zentiva, K.S. | Process for preparing dabigatran |
US20110123635A1 (en) * | 2008-07-14 | 2011-05-26 | Boehringer Ingelheim International Gmbh | Method for manufacturing medicinal compounds containing dabigatran |
CA2734804A1 (en) * | 2008-08-19 | 2010-02-25 | Boehringer Ingelheim International Gmbh | Use of dabigatranetexilate for treating patients with pulmonary hypertension |
CZ2008669A3 (en) * | 2008-10-24 | 2010-05-05 | Zentiva, A. S. | Process for preparing dabigatran and intermediates thereof |
KR101822368B1 (en) * | 2009-02-02 | 2018-01-31 | 베링거 인겔하임 인터내셔날 게엠베하 | Lyophilised Dabigatran |
EP2647375A1 (en) | 2009-05-14 | 2013-10-09 | Boehringer Ingelheim International Gmbh | Combination of vargatef and dabigatran for the treatment of oncological and fibrotic diseases |
PL2470187T3 (en) | 2009-08-24 | 2014-01-31 | Boehringer Ingelheim Int | Emergency interventions of active charcoal with dabigatran etexilate overdosing |
CN102050815B (en) * | 2009-11-06 | 2014-04-02 | 北京美倍他药物研究有限公司 | Dabigatran ester derivatives as prodrug |
CN102050814B (en) * | 2009-11-06 | 2014-05-28 | 北京美倍他药物研究有限公司 | Ester derivatives of dabigatran |
US8399678B2 (en) * | 2009-11-18 | 2013-03-19 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dabigatran etexilate |
AR079944A1 (en) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | NEUTRALIZING ANTIBODY OF THE ACTIVITY OF AN ANTICOAGULANT |
HUP1000069A2 (en) | 2010-02-02 | 2012-05-02 | Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag | New salts for the preparation of pharmaceutical composition |
JP5844287B2 (en) | 2010-02-11 | 2016-01-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Macrocycles as factor XIA inhibitors |
PL2542224T3 (en) | 2010-03-01 | 2014-12-31 | Ratiopharm Gmbh | Dabigatran etexilate-containing oral pharmaceutical composition |
WO2011110478A1 (en) | 2010-03-08 | 2011-09-15 | Ratiopharm Gmbh | Dabigatran etexilate-containing pharmaceutical composition |
US20130177652A1 (en) | 2010-07-01 | 2013-07-11 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts |
EP2590962A2 (en) | 2010-07-09 | 2013-05-15 | Esteve Química, S.A. | Process of preparing a thrombin specific inhibitor |
US20130116441A1 (en) | 2010-07-09 | 2013-05-09 | Esteve Quimica, S.A. | Intermediates and process for preparing a thrombin specific inhibitor |
WO2012027543A1 (en) | 2010-08-25 | 2012-03-01 | Teva Pharmaceuticals Usa, Inc. | Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof |
WO2012077136A2 (en) | 2010-12-06 | 2012-06-14 | Msn Laboratories Limited | Process for the preparation of benzimidazole derivatives and its salts |
EP2671582B1 (en) | 2011-02-01 | 2016-07-13 | Kyowa Hakko Kirin Co., Ltd. | Ring-fused heterocyclic derivative |
PE20140964A1 (en) | 2011-03-30 | 2014-08-17 | Boehringer Ingelheim Int | ANTICOAGULANT ANTIDOTES |
HUP1100244A2 (en) | 2011-05-11 | 2012-11-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Pharmaceutical intermediates and process for their production |
CN102250099B (en) * | 2011-05-16 | 2013-10-16 | 中国药科大学 | Non-peptide thrombin inhibitors as well as preparation method and medical application thereof |
CN102838588B (en) * | 2011-06-24 | 2014-03-19 | 中国药科大学 | Oral thrombin inhibitors, preparation methods and medical uses thereof |
HUE032862T2 (en) * | 2011-07-25 | 2017-11-28 | Dritte Patentportfolio Beteili | Amidoxime carboxylic acid esters of dabigatran as prodrugs and their use as medicament |
TW201319068A (en) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | Cyclic P1 linkers as factor XIa inhibitors |
TW201311689A (en) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | Novel macrocycles as factor XIa inhibitors |
WO2013024394A1 (en) * | 2011-08-12 | 2013-02-21 | Alembic Pharmaceuticals Limited | Novel reference markers of dabigatran etexilate |
CN102993174A (en) * | 2011-09-08 | 2013-03-27 | 天津药物研究院 | Dabigatran etexilate derivative as a prodrug |
CN102993175B (en) * | 2011-09-08 | 2014-08-13 | 天津药物研究院 | Dabigatran derivatives, and preparation method and application thereof |
CA2851810C (en) | 2011-10-14 | 2020-01-07 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
EP2899183B1 (en) | 2011-10-14 | 2018-09-19 | Bristol-Myers Squibb Company | Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors |
US9079929B2 (en) | 2011-10-14 | 2015-07-14 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors |
KR20140107302A (en) | 2011-12-22 | 2014-09-04 | 베링거 인겔하임 인터내셔날 게엠베하 | Immediate release multi unit pellet system |
WO2013111163A2 (en) | 2012-01-20 | 2013-08-01 | Cadila Healthcare Limited | Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof |
WO2013110567A1 (en) | 2012-01-24 | 2013-08-01 | Boehringer Ingelheim International Gmbh | Novel orally administered dabigatran formulation |
KR102090242B1 (en) | 2012-02-21 | 2020-03-18 | 에스테베 파마슈티칼스 에스에이 | Oral pharmaceutical compositions of dabigatran etexilate |
EP2631234A1 (en) | 2012-02-23 | 2013-08-28 | Esteve Química, S.A. | Solid forms of dabigatran etexilate mesylate and processes for their preparation |
WO2013144971A1 (en) | 2012-03-27 | 2013-10-03 | Cadila Healthcare Limited | New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them |
WO2013150545A2 (en) | 2012-04-02 | 2013-10-10 | Msn Laboratories Limited | Process for the preparation of benzimidazole derivatives and salts thereof |
CN103387566B (en) * | 2012-05-09 | 2015-09-09 | 上海医药工业研究院 | Prepare the method for 3-[[[2-[[(4-cyano-phenyl) is amino] methyl]-1-methyl isophthalic acid H-benzoglyoxaline-5-base] carbonyl] (pyridine-2-base) is amino] ethyl propionate |
CN103420980A (en) * | 2012-05-22 | 2013-12-04 | 北京美倍他药物研究有限公司 | Dabigatran derivatives |
US20130345262A1 (en) | 2012-06-25 | 2013-12-26 | Boehringer Ingelheim International Gmbh | Method for prevention of stroke |
US9365544B2 (en) * | 2012-07-16 | 2016-06-14 | Interquim, S.A. | Process for the preparation of intermediates for the synthesis of Dabigatran Etexilate, and crystalline forms of said intermediates |
CN102766134B (en) * | 2012-07-19 | 2014-06-25 | 北京普禄德医药科技有限公司 | Dabigatran etexilate derivative and preparation method and application thereof |
JP6193233B2 (en) * | 2012-07-31 | 2017-09-06 | 協和発酵キリン株式会社 | Fused heterocyclic compounds |
KR20150038369A (en) | 2012-08-03 | 2015-04-08 | 브리스톨-마이어스 스큅 컴퍼니 | Dihydropyridone p1 as factor xia inhibitors |
CN104507924B (en) | 2012-08-03 | 2018-01-23 | 百时美施贵宝公司 | Dihydropyridone P1 is as factor XIA inhibitors |
WO2014041559A2 (en) * | 2012-08-27 | 2014-03-20 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Process for the preparation of dabigatran etexilate and intermediates thereof |
WO2014060545A1 (en) | 2012-10-19 | 2014-04-24 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical compositions of dabigatran free base |
EP2722034B1 (en) | 2012-10-19 | 2020-09-16 | Sanovel Ilac Sanayi ve Ticaret A.S. | Oral pharmaceutical formulations comprising dabigatran |
US9399616B2 (en) | 2012-10-22 | 2016-07-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of 4-aminobenzoamidine dihydrochloride |
US9533971B2 (en) | 2012-10-29 | 2017-01-03 | Biophore India Pharmaceuticals Pvt. Ltd | Process for the synthesis of dabigatran and its intermediates |
US10077251B2 (en) | 2012-10-29 | 2018-09-18 | Biophore India Pharmaceuticals Pvt. Ltd. | Process for the synthesis of Dabigatran Etexilate and its intermediates |
CN102977077A (en) * | 2012-11-28 | 2013-03-20 | 浙江燎原药业有限公司 | Method for preparing dabigatran etexilate intermediate |
EP2740471B1 (en) | 2012-12-07 | 2015-05-27 | Hexal AG | Oral pharmaceutical composition comprising dabigatran etexilate |
CN103044404A (en) * | 2013-01-14 | 2013-04-17 | 中国药科大学 | Dabigatran derivatives, and preparation method and application thereof in antithrombosis |
JP6479763B2 (en) | 2013-03-25 | 2019-03-06 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Substituted azole containing tetrahydroisoquinolines as factor XIA inhibitors |
CN103224469A (en) * | 2013-05-16 | 2013-07-31 | 上海应用技术学院 | Pradaxa analogue with fluorine-containing group modified benzene ring as center and synthesis method thereof |
UY35592A (en) | 2013-06-03 | 2014-12-31 | Bayer Pharma AG | BENZOXAZOLES REPLACED |
EP3004086A1 (en) | 2013-06-03 | 2016-04-13 | Bayer Pharma Aktiengesellschaft | Substituted benzoxazoles |
CN103288744A (en) * | 2013-06-04 | 2013-09-11 | 上海应用技术学院 | Fluorine group-containing-modified dabigatran etexilate analogue and synthetic method thereof |
EP2853260A1 (en) | 2013-09-27 | 2015-04-01 | ratiopharm GmbH | Pharmaceutical preparation comprising dabigatran etexilate bismesylate |
WO2015116886A1 (en) | 2014-01-31 | 2015-08-06 | Bristol-Myers Squibb Company | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
NO2760821T3 (en) | 2014-01-31 | 2018-03-10 | ||
IN2014MU00675A (en) | 2014-02-26 | 2015-10-23 | Megafine Pharma P Ltd | |
WO2015137680A1 (en) * | 2014-03-10 | 2015-09-17 | 동아에스티 주식회사 | Pharmaceutical composition for treating or preventing stroke and systemic embolism |
WO2015145462A1 (en) | 2014-03-26 | 2015-10-01 | Cadila Healthcare Limited | Pharmaceutical compositions of dabigatran |
EP2929884A1 (en) | 2014-04-11 | 2015-10-14 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical combinations of dabigatran and h2-receptor antagonists |
EP2933002A1 (en) | 2014-04-11 | 2015-10-21 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical combinations of dabigatran and proton pump inhibitors |
CN104230888A (en) * | 2014-06-03 | 2014-12-24 | 长春工业大学 | Preparation method of benzimidazole compound |
CN105218519A (en) * | 2014-06-04 | 2016-01-06 | 天津药物研究院 | A kind of preparation method of dabigatran etexilate intermediate |
CN104003977B (en) * | 2014-06-05 | 2016-04-13 | 雅本化学股份有限公司 | The preparation method of N-(2-chloromethyl-1-methyl isophthalic acid H-benzoglyoxaline-5-acyl group)-N-(pyridine-2-base)-3-alanine ethyl ester |
DE102014108210A1 (en) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | rodenticide |
CN104045628B (en) * | 2014-06-13 | 2019-04-09 | 深圳翰宇药业股份有限公司 | The purification process of benzimidizole derivatives |
CN105315257A (en) * | 2014-06-24 | 2016-02-10 | 华仁药业股份有限公司 | Synthetic and purifying method of dabigatran etexilate |
WO2016019848A1 (en) * | 2014-08-06 | 2016-02-11 | 四川海思科制药有限公司 | Dabigatran thioester derivative, preparation method therefor, and pharmaceutical use thereof |
WO2016019849A1 (en) * | 2014-08-06 | 2016-02-11 | 四川海思科制药有限公司 | Dabigatran carboalkoxy derivative, preparation method therefor, and pharmaceutical use thereof |
NO2721243T3 (en) | 2014-10-01 | 2018-10-20 | ||
CA3001495C (en) | 2014-11-03 | 2021-07-20 | Solipharma Llc | Formulations of dabigatran etexilate or dabigatran etexilate salts and preparation methods thereof |
CN104592204B (en) * | 2014-12-26 | 2017-05-17 | 华润赛科药业有限责任公司 | Dabigatran derivatives as well as preparation method and application thereof |
CN104650037A (en) * | 2014-12-30 | 2015-05-27 | 青岛黄海制药有限责任公司 | Synthesis method of dabigatran etexilate |
TR201502223A2 (en) | 2015-02-25 | 2016-09-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical combinations of dronedarone and dabigatran |
CN104628733A (en) * | 2015-03-02 | 2015-05-20 | 中国药科大学 | Tetrahydrobenzo[4,5] imidazo[1,2-a] pyrazine thrombin inhibitors |
WO2016205482A1 (en) | 2015-06-19 | 2016-12-22 | Bristol-Myers Squibb Company | Diamide macrocycles as factor xia inhibitors |
CN104987323B (en) * | 2015-07-10 | 2017-08-22 | 浙江美诺华药物化学有限公司 | A kind of preparation method of dabigatran etcxilate |
EP3324946A1 (en) | 2015-07-20 | 2018-05-30 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical formulations of dabigatran free base |
EP3328852B1 (en) | 2015-07-29 | 2021-04-28 | Bristol-Myers Squibb Company | Factor xia macrocyclic inhibitors bearing a non-aromatic p2' group |
WO2017023992A1 (en) | 2015-08-05 | 2017-02-09 | Bristol-Myers Squibb Company | Novel substituted glycine derived fxia inhibitors |
CN105294651A (en) * | 2015-09-23 | 2016-02-03 | 烟台东诚药业集团股份有限公司 | Method for synthesizing and preparing pradaxa formamidine intermediates |
CN106866626A (en) * | 2015-12-14 | 2017-06-20 | 天津药物研究院有限公司 | A kind of preparation method of dabigatran etexilate intermediate |
CN105481831B (en) * | 2015-12-16 | 2018-06-12 | 开封明仁药业有限公司 | A kind of method for preparing dabigatran etexilate intermediate |
WO2017111637A1 (en) | 2015-12-23 | 2017-06-29 | Zaklady Farmaceutyczne Polpharma Sa | Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof |
CN105566297A (en) * | 2015-12-31 | 2016-05-11 | 哈药集团技术中心 | Preparation method of dabigatran etexilate mesylate |
JP2019507167A (en) | 2016-03-02 | 2019-03-14 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Diamide macrocycle with factor XIA inhibitory activity |
CN105669651B (en) * | 2016-03-07 | 2018-03-06 | 山东罗欣药业集团股份有限公司 | A kind of preparation technology of dabigatran etexilate methanesulfonate |
CN106397400A (en) * | 2016-04-14 | 2017-02-15 | 江苏康缘药业股份有限公司 | Preparation method for dabigatran etexilate |
TR201606697A2 (en) | 2016-05-20 | 2017-12-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | NEW ORAL PHARMACEUTICAL FORMULATIONS OF DABIGATRA |
CN106349221A (en) * | 2016-08-29 | 2017-01-25 | 常州市阳光药业有限公司 | Preparation method of high-purity dabigatran etexilate |
WO2018104387A1 (en) | 2016-12-07 | 2018-06-14 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Multilayered tablet compositions of dabigatran |
TR201617984A2 (en) | 2016-12-07 | 2018-06-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN |
JP2018184375A (en) | 2017-04-27 | 2018-11-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Tablet comprising dabigatran etexilate or pharmaceutically acceptable salt thereof and method for producing the same |
WO2019004980A2 (en) | 2017-05-10 | 2019-01-03 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Solid oral pharmaceutical compositions of dabigatran etexilate |
TR201706848A2 (en) | 2017-05-10 | 2018-11-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | SOLID ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING DABIGATRAN ETEXCLATE |
CN109010249A (en) * | 2017-06-08 | 2018-12-18 | 上海美悦生物科技发展有限公司 | Injection dabigatran etcxilate pharmaceutical composition and its preparation method and application |
KR20190036857A (en) | 2017-09-28 | 2019-04-05 | 한미약품 주식회사 | Composite capsule formulation comprising dabigatran etexilate |
TR201722186A2 (en) | 2017-12-27 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical compositions of dabigatran |
TR201722323A2 (en) | 2017-12-27 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Oral pharmaceutical compositions of dabigatran |
TR201722630A2 (en) | 2017-12-28 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | |
CN111954532A (en) * | 2018-04-13 | 2020-11-17 | 上海交通大学医学院附属瑞金医院 | Anti-tumor multi-drug resistance of heteroaryl amide compounds, application of heteroaryl amide compounds in treating cancer and protein-drug molecular compound |
CN108864047A (en) * | 2018-07-02 | 2018-11-23 | 河南师范大学 | A kind of preparation method of non-peptide batroxobin inhibitor dabigatran etcxilate |
EP3771465A1 (en) | 2019-08-01 | 2021-02-03 | Zaklady Farmaceutyczne Polpharma SA | Pharmaceutical composition comprising dabigatran etexilate |
CN111606885A (en) * | 2020-06-18 | 2020-09-01 | 安徽鼎旺医药有限公司 | Dabigatran etexilate mesylate and preparation method thereof |
CN113929661A (en) * | 2020-06-29 | 2022-01-14 | 石药集团恩必普药业有限公司 | Dabigatran etexilate intermediate and preparation method thereof |
EP4070658A1 (en) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Use of anticoagulant active compounds as rodenticide |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4675405A (en) * | 1984-09-21 | 1987-06-23 | American Home Products Corporation | Quinoline compounds as antiallergic and antithrombotic agents |
DE4129603A1 (en) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | CONDENSED 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THESE COMPOUNDS |
US5416099A (en) * | 1991-10-29 | 1995-05-16 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
ZA928276B (en) * | 1991-10-31 | 1993-05-06 | Daiichi Seiyaku Co | Aromatic amidine derivates and salts thereof. |
CA2134192A1 (en) * | 1993-11-12 | 1995-05-13 | Michael L. Denney | 5, 6-bicyclic glycoprotein iib/iiia antagonists |
-
1998
- 1998-01-15 PE PE1998000030A patent/PE121699A1/en not_active IP Right Cessation
- 1998-01-23 MY MYPI98000290A patent/MY129408A/en unknown
- 1998-02-16 ES ES98909468T patent/ES2199426T4/en not_active Expired - Lifetime
- 1998-02-16 SK SK1121-99A patent/SK285432B6/en active Protection Beyond IP Right Term
- 1998-02-16 PL PL98335154A patent/PL195551B1/en unknown
- 1998-02-16 WO PCT/EP1998/000865 patent/WO1998037075A1/en active IP Right Grant
- 1998-02-16 CN CN98802623A patent/CN1088702C/en not_active Expired - Lifetime
- 1998-02-16 TR TR1999/02017T patent/TR199902017T2/en unknown
- 1998-02-16 CZ CZ0291599A patent/CZ297768B6/en not_active IP Right Cessation
- 1998-02-16 RS YUP-387/99A patent/RS49686B/en unknown
- 1998-02-16 HU HU0001116A patent/HU223754B1/en active Protection Beyond IP Right Term
- 1998-02-16 AU AU63991/98A patent/AU742593C/en not_active Expired
- 1998-02-16 DE DE122008000020C patent/DE122008000020I1/en active Pending
- 1998-02-16 KR KR1019997007335A patent/KR100619458B1/en active IP Right Review Request
- 1998-02-16 EA EA199900746A patent/EA003697B1/en active IP Right Grant
- 1998-02-16 DK DK98909468T patent/DK0966454T3/en active
- 1998-02-16 JP JP53623498A patent/JP3343359B2/en not_active Expired - Lifetime
- 1998-02-16 SI SI9830479T patent/SI0966454T1/en unknown
- 1998-02-16 PT PT98909468T patent/PT966454E/en unknown
- 1998-02-16 BR BRPI9807843-7A patent/BR9807843B1/en not_active IP Right Cessation
- 1998-02-16 EP EP98909468A patent/EP0966454B1/en not_active Expired - Lifetime
- 1998-02-16 EE EEP199900359A patent/EE04716B1/en active Protection Beyond IP Right Term
- 1998-02-16 DE DE59808281T patent/DE59808281D1/en not_active Expired - Lifetime
- 1998-02-16 AT AT98909468T patent/ATE239712T1/en active
- 1998-02-16 NZ NZ337323A patent/NZ337323A/en not_active IP Right Cessation
- 1998-02-16 CA CA002277949A patent/CA2277949C/en not_active Expired - Lifetime
- 1998-02-16 IL IL13081298A patent/IL130812A/en active Protection Beyond IP Right Term
- 1998-02-17 HR HR980082A patent/HRP980082B1/en not_active IP Right Cessation
- 1998-02-17 CO CO98008407A patent/CO4920237A1/en unknown
- 1998-02-17 EG EG18498A patent/EG24144A/en active
- 1998-02-18 TW TW087102265A patent/TW588047B/en not_active IP Right Cessation
- 1998-02-18 AR ARP980100722A patent/AR010896A1/en active Pending
- 1998-05-06 SA SA98190047A patent/SA98190047B1/en unknown
-
1999
- 1999-08-10 BG BG103655A patent/BG64558B1/en active Active
- 1999-08-17 NO NO19993945A patent/NO313879B1/en not_active IP Right Cessation
-
2000
- 2000-07-10 HK HK00104207A patent/HK1025096A1/en not_active IP Right Cessation
-
2008
- 2008-05-09 LT LTPA2008008C patent/LTC0966454I2/en unknown
- 2008-05-14 LU LU91437C patent/LU91437I2/en unknown
- 2008-05-28 NL NL300349C patent/NL300349I2/en unknown
- 2008-06-06 FR FR08C0025C patent/FR08C0025I2/en active Active
- 2008-07-31 NO NO2008012C patent/NO2008012I2/en not_active IP Right Cessation
-
2021
- 2021-02-05 NO NO2021005C patent/NO2021005I1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE9900359A (en) | Disubstituted bicyclic heterocycles, their preparation and use as pharmaceuticals | |
EE9900147A (en) | Oxadiazoles, methods for their preparation and use as pharmaceuticals | |
PT911340E (en) | SUBSTITUTED ISOKINOLINES-3-CARBOXAMIDES, ITS PREPARATION AND USE AS DRUGS | |
EE9900018A (en) | Substituted pyridines, their use and pharmaceutical compositions | |
EE200000468A (en) | The compounds, their use and the pharmaceutical composition | |
EE04151B1 (en) | Acylpiperazinylpyrimidine Derivatives, Their Preparation and Use as Medicaments | |
FI961219A (en) | Chemical compounds, their preparation and use | |
EE04721B1 (en) | Phenylxanthine derivatives, processes for their preparation and use | |
EE200000621A (en) | Anti-picornaviral compounds, their preparation and use | |
EE9800145A (en) | Phenylamidine derivatives, methods for their preparation and their use as medicaments | |
EE04398B1 (en) | Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ol, process for their preparation and use as pharmaceuticals | |
EE03996B1 (en) | Pharmaceutical compositions, process for their preparation and use | |
FI941914A (en) | 2-amino-4-quinoline dihydropyridines, methods for their preparation and their use | |
EE03387B1 (en) | Combined pharmaceutical preparation, its use and method for its preparation | |
EE04260B1 (en) | Pharmaceutical composition, process for its preparation and use | |
TR199501553A2 (en) | Sefem compounds and their use as pharmaceuticals. | |
FI971317A0 (en) | New heterocyclic, substituted imidazoloquinoxalinones, their preparation and use | |
EE200000018A (en) | 6-Pyrrolidin-2-ylpyridines, their Preparation and Therapeutic Use | |
EE9900560A (en) | 5-Naphthalen-1-yl-1,3-dioxane derivatives, their preparation and therapeutic use | |
ZA981275B (en) | Disubstituted bicyclic heterocycles, the preparation and the use thereof as pharmaceutical compositions. | |
FI972988A0 (en) | Methods and pharmaceutical compositions using desmethylselegiline | |
EE200200229A (en) | Diarylenines, composition and pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC1A | Change of owner name | ||
KB4A | Valid patent at the end of a year |
Effective date: 20061231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20071231 |
|
AA1Y | Spc filed |
Free format text: PRODUCT NAME: PRADAXA- DABIGATRAANETEKSILAAT (MESUELAADINA) Spc suppl protection certif: C20080003 Filing date: 20080918 |
|
FG1Y | Spc granted |
Free format text: PRODUCT NAME: PRADAXA - DABIGATRAANETEKSILAAT (MESUELAADINA) Spc suppl protection certif: C20080003 00018 Filing date: 20080918 Extension date: 20230216 |
|
LD4A | Amendment in the specification | ||
KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |
|
SPCM | Correction and amendment to the data concerning application for a supplementary protection certificate |
Spc suppl protection certif: C20080003 00018 Extension date: 20230320 |
|
SPCT | Party data change related to a supplementary protection certificate |
Spc suppl protection certif: 00018 |